Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

153
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
153
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

257
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
257
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

173
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
173
Glucose Transporters01:27

Glucose Transporters

22.7K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.7K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.2K
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

1.6K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hormones, hormesis, and holistic obesity care.

JPMA. The Journal of the Pakistan Medical Association·2026
Same author

Baroneurosis.

JPMA. The Journal of the Pakistan Medical Association·2026
Same author

Baropsychology.

JPMA. The Journal of the Pakistan Medical Association·2026
Same author

Water and weight: the role of hydration in weight management.

JPMA. The Journal of the Pakistan Medical Association·2026
Same author

A quantum approach to the endocrinology of obesity.

Endocrine connections·2026
Same author

A Multidisciplinary Approach to Addressing Barriers in Osteoporosis Screening, Diagnosis, Therapy Sequencing, and Adherence in India.

Cureus·2026

Related Experiment Video

Updated: Jun 26, 2025

Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT
07:07

Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT

Published on: May 2, 2017

14.0K

Glucokathexis.

Sanjay Kalra1, Saurabh Arora2, Nitin Kapoor3

  • 1Department of Endocrinology, Bharti Hospital, Karnal, India;University Center for Research & Development, Chandigarh University, India.

JPMA. the Journal of the Pakistan Medical Association
|May 16, 2024
PubMed
Summary

Glucokathexis, a state of low plasma glucose despite sufficient precursors, is defined. This metabolic medicine rubric outlines conditions causing true and pseudo-glucokathexis.

Keywords:
Autoimmunity, counter-regulatory mechanism, diabetes, glucose, hypoglycaemia, insulin, insulin resistance, nutrition.

More Related Videos

Biochemical Titration of Glycogen In vitro
07:16

Biochemical Titration of Glycogen In vitro

Published on: November 24, 2013

28.4K
Spectrophotometric Methods for the Study of Eukaryotic Glycogen Metabolism
07:59

Spectrophotometric Methods for the Study of Eukaryotic Glycogen Metabolism

Published on: August 19, 2021

3.7K

Related Experiment Videos

Last Updated: Jun 26, 2025

Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT
07:07

Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT

Published on: May 2, 2017

14.0K
Biochemical Titration of Glycogen In vitro
07:16

Biochemical Titration of Glycogen In vitro

Published on: November 24, 2013

28.4K
Spectrophotometric Methods for the Study of Eukaryotic Glycogen Metabolism
07:59

Spectrophotometric Methods for the Study of Eukaryotic Glycogen Metabolism

Published on: August 19, 2021

3.7K

Area of Science:

  • Metabolic Medicine
  • Clinical Biochemistry

Background:

  • Glucokathexis is a poorly understood clinical state.
  • Characterized by low plasma glucose with adequate glucose precursor stores.

Purpose of the Study:

  • To define glucokathexis and stimulate research in this area.
  • To categorize conditions leading to glucokathexis.

Main Methods:

  • Literature review and conceptual framework development.
  • Classification of etiologies for glucokathexis.

Main Results:

  • Definition of glucokathexis provided.
  • Categorization of true and pseudo-glucokathexis presented.
  • Examples of causative conditions listed.

Conclusions:

  • Glucokathexis represents a distinct clinical entity.
  • Further investigation into the pathophysiology and management of glucokathexis is warranted.